/PRNewswire/ Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization.
Harbour BioMed, HanAll s licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally.
/PRNewswire/ Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or SKB378 as.